PARDES BIOSCIENCES, INC.

(PRDS)
  Report
Real-time Estimate Cboe BZX  -  12:29 2022-07-05 pm EDT
3.270 USD   +4.81%
06/20PARDES BIOSCIENCES, INC.(NASDAQGM : PRDS) added to S&P Global BMI Index
CI
06/10PARDES BIOSCIENCES, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/09PARDES BIOSCIENCES, INC. : Other Events (form 8-K)
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Nasdaq
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
3 2.84 3.01 3.07 3.12 Last
594343 297253 524030 258417 118618 Volume
-13.29% -5.33% +5.99% +1.99% +1.63% Change
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -103 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,81x
Yield 2022 -
Sales 2023 765 M - -
Net income 2023 580 M - -
Net Debt 2023 - - -
P/E ratio 2023 0,35x
Yield 2023 -
Capitalization 194 M 194 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 0,25x
Nbr of Employees 47
Free-Float 72,4%
More Financials
Company
Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics to improve the lives of patients suffering from life-threatening diseases. Its lead candidate, PBI-0451, is in clinical development and is developed to treat and prevent coronaviral (CoV) infections. It has built a discovery platform designed to target reactive... 
More about the company
All news about PARDES BIOSCIENCES, INC.
06/20PARDES BIOSCIENCES, INC.(NASDAQGM : PRDS) added to S&P Global BMI Index
CI
06/10PARDES BIOSCIENCES, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/09PARDES BIOSCIENCES, INC. : Other Events (form 8-K)
AQ
06/09Pardes Biosciences, Inc. Provides Updates on PBI-0451 Program
CI
06/01Pardes Biosciences to Present at Jefferies Global Healthcare Conference
AQ
05/10PARDES BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
05/10Earnings Flash (PRDS) PARDES BIOSCIENCES Reports Q1 Loss $-0.38
MT
05/10Pardes Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
CI
05/10Pardes Biosciences Reports First Quarter 2022 Financial Results and Provides Business U..
AQ
03/29PARDES BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
03/29PARDES BIOSCIENCES : Reports Full Year 2021 Financial Results and Provides Business Update..
PU
03/29PARDES BIOSCIENCES, INC. : Regulation FD Disclosure (form 8-K)
AQ
03/29Pardes Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, ..
CI
03/29Pardes Biosciences Reports Full Year 2021 Financial Results and Provides Business Updat..
AQ
03/24PARDES BIOSCIENCES : ICAR 2022 Presentation
PU
More news
News in other languages on PARDES BIOSCIENCES, INC.
06/09Pardes Biosciences, Inc. fait le point sur le programme PBI-0451
05/10Pardes Biosciences, Inc. annonce ses résultats pour le premier trimestre clos le 31 mar..
03/29Pardes Biosciences, Inc. annonce ses résultats pour l'année complète se terminant le 31..
03/02Pardes Biosciences nomme Thomas G. Wiggans au poste de PDG
03/02Pardes Biosciences, Inc. annonce des changements au conseil d'administration
More news
Analyst Recommendations on PARDES BIOSCIENCES, INC.
More recommendations
Chart PARDES BIOSCIENCES, INC.
Duration : Period :
Pardes Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PARDES BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 3,12 $
Average target price 19,00 $
Spread / Average Target 509%
EPS Revisions
Managers and Directors
Thomas G. Wiggans Chairman & Chief Executive Officer
Heidi Henson Chief Financial Officer
Lee D. Arnold Chief Scientific Officer
Mark Auerbach Director
J. Jay Lobell Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PARDES BIOSCIENCES, INC.-80.94%194
MODERNA, INC.-40.96%59 644
IQVIA HOLDINGS INC.-23.78%40 704
LONZA GROUP AG-31.09%40 503
SEAGEN INC.16.50%33 154
CELLTRION, INC.-9.34%19 151